BIONTECH Stock Price, News & Analysis

Pfizer and BioNTech have secured an advance purchase agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine in 2021. The initial doses are expected in Q1 2021, subject to supply agreements. This collaboration is part of COVAX's initiative to ensure equitable vaccine access for 92 low- and lower-middle-income countries at a not-for-profit price. The agreement underscores the companies' commitment to global health, as both aim to enhance vaccine accessibility worldwide.

Pfizer and BioNTech SE have secured an advance purchase agreement with COVAX for up to 40 million doses of their COVID-19 vaccine, aimed at equitable distribution. The doses will be supplied throughout 2021, with the first expected in Q1, 2021. This initiative supports 92 low-income countries, ensuring access at a not-for-profit price. Both companies emphasize their commitment to providing affordable vaccines globally, aimed at combating the pandemic. The financial specifics of the agreement remain undisclosed.

The in vitro study conducted by Pfizer and BioNTech demonstrates that sera from individuals immunized with their COVID-19 vaccine (BNT162b2) can neutralize the U.K. variant of SARS-CoV-2 (B.1.1.7). The study published on bioRxiv indicates that sera inhibited the pseudovirus featuring the U.K. strain spike protein, suggesting that the vaccine may remain effective against this variant. The companies emphasize the need for continuous monitoring and the flexibility of their mRNA platform to adapt to potential future virus strain changes.

Pfizer and BioNTech announced new study results from the University of Texas Medical Branch showing that antibodies from recipients of the Pfizer-BioNTech COVID-19 vaccine effectively neutralize a variant of the virus with a key mutation (N501Y) linked to increased transmissibility. The study suggests the vaccine remains effective against this mutation, indicating that its immune response is preserved against emerging strains. Further monitoring is required for ongoing evaluation of the vaccine's effectiveness against new variants. The vaccine is authorized for emergency use but not yet fully licensed by the FDA.

BioNTech (Nasdaq: BNTX) announced a breakthrough in autoimmune disease treatment with a novel non-inflammatory mRNA vaccine. This vaccine, developed in collaboration with TRON and the University Medical Center Mainz, demonstrated disease activity suppression in mouse models of multiple sclerosis (MS). It allows for tailored treatment addressing disease-specific antigens while avoiding systemic immune suppression. Initial results show potential for mRNA therapeutics to target complex autoimmune conditions without inducing autoantibodies or compromising responses to other vaccinations, further expanding BioNTech's immunology pipeline.

BioNTech SE (Nasdaq: BNTX) announced that CEO Ugur Sahin will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 10:50 AM ET. The event will be available through a live webcast on the company's Investor Relations page. A replay will be archived for 30 days. BioNTech is known for its innovative immunotherapy solutions and mRNA vaccine candidates for serious diseases, including cancer and infectious diseases, and collaborates with major pharmaceutical companies.

Pfizer and BioNTech announced an agreement to supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY®, to the EU in 2021. This expands total doses to 300 million, following an earlier deal.

CEO Albert Bourla emphasized the commitment to rapid vaccine distribution as the virus continues to pose significant public health risks. The vaccine is produced in European manufacturing sites and is authorized for emergency use but not FDA-approved. Pfizer and BioNTech project potential supply of up to 1.3 billion doses worldwide by the end of 2021.

The European Union has ordered an additional 100 million doses of COMIRNATY, the COVID-19 vaccine developed by Pfizer and BioNTech, bringing the total to 300 million doses for 27 member states. Deliveries are expected throughout 2020 and 2021. The agreement follows the European Commission's decision to exercise its purchase option under an Advanced Purchase Agreement from November 11, 2020. The vaccine aims to support vaccination campaigns that began recently, with the goal to immunize 150 million Europeans.